NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis $1.21 +0.05 (+4.31%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.20 0.00 (-0.41%) As of 09/18/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Allarity Therapeutics Stock (NASDAQ:ALLR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allarity Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.2250-Day Range$1.11▼$1.4352-Week Range$0.77▼$1.84Volume185,434 shsAverage Volume95,152 shsMarket Capitalization$19.25 millionP/E RatioN/ADividend YieldN/APrice Target$10.25Consensus RatingHold Company Overview Allarity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing personalized cancer treatments. The company uses its Drug Response Predictor (DRP) technology to analyze tumor biology and identify patients who may be more likely to respond to specific therapies. Allarity’s development programs have included dovitinib, an oral multikinase inhibitor investigated for use in advanced cancers, as well as other oncology candidates and drug-specific DRP companion diagnostics. The company’s approach is intended to support patient selection and improve the efficiency of clinical development by matching treatments with patients whose tumors are predicted to be sensitive to them. The business has roots in Denmark and the United States. It was previously known as Oncology Venture A/S before adopting the Allarity Therapeutics name, reflecting its emphasis on precision oncology and its proprietary response-prediction platform. Its programs remain focused on the development of targeted therapies and diagnostic tools for cancer care.AI Generated. May Contain Errors. Read More Allarity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreALLR MarketRank™: Allarity Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 763rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAllarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAllarity Therapeutics has a consensus price target of $10.25, representing about 747.1% upside from its current price of $1.21.Amount of Analyst CoverageAllarity Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Allarity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.92) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allarity Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allarity Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllarity Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Allarity Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.75% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 12.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for ALLR on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.16% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by Institutions11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLR Stock News HeadlinesAllarity Gets Japanese Patent For Stenoparib DRP Companion Diagnostic; Protection Through 2039September 15, 2026 | rttnews.comAllarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib DevelopmentSeptember 15, 2026 | globenewswire.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal. | American Alternative (Ad)Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementSeptember 11, 2026 | finanznachrichten.deAllarity Acquisition Seeks Nasdaq Listing With Proposed $100 Mln IPOSeptember 11, 2026 | rttnews.comAllarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementSeptember 11, 2026 | globenewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing CampaignAugust 15, 2026 | finanznachrichten.deAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing CampaignAugust 14, 2026 | globenewswire.comSee More Headlines ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed this year? Allarity Therapeutics' stock was trading at $1.08 at the beginning of the year. Since then, ALLR shares have increased by 12.0% and is now trading at $1.21. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) released its earnings results on Friday, August, 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. When did Allarity Therapeutics' stock split? Shares of Allarity Therapeutics reverse split before market open on Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How will Allarity Therapeutics' stock buyback program work? Allarity Therapeutics' board authorized a share buyback program on Monday, March 3rd 2025, which authorizes the company to repurchase $5,000,000 in shares, according to EventVestor. This means that the company could purchase up to 128.1% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allarity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE). Company Calendar Last Earnings8/14/2026Today9/19/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ALLR's financial health is in the Green zone, according to TradeSmith. ALLR has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALLR CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees8Year Founded2004Price Target and Rating Average Price Target for Allarity Therapeutics$10.25 High Price Target$10.25 Low Price Target$10.25 Potential Upside/Downside+747.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.23 million Net MarginsN/A Pretax Margin-3,575.07% Return on Equity-152.77% Return on Assets-46.50% Debt Debt-to-Equity RatioN/A Current Ratio1.11 Quick Ratio1.11 Sales & Book Value Annual Sales$320 thousand Price / Sales60.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.98Miscellaneous Outstanding Shares15,910,000Free Float15,886,000Market Cap$19.25 million OptionableNot Optionable Beta0.56 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ALLR) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
